Select Publications

63. Buzdar AU et al. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 1989;12(2):123-8. Abstract

64. Buzdar AU et al. Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute. NCI Monogr 1986;(1):81-5. Abstract

65. Buzdar AU et al. Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. Cancer 1984;53(3):384-9. Abstract

66. Buzdar AU et al. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer 1978;41(3):1064-75. Abstract

67. Jones SE et al. Adjuvant treatment of node-positive breast cancer with adriamycin-cyclophosphamide with or without radiation therapy: Interim results of an ongoing clinical trial. Recent Results Cancer Res 1982;80:162-9. Abstract

68. Brooks RJ et al. Adjuvant chemotherapy of axillary node-negative carcinoma of the breast using doxorubicin and cyclophosphamide. NCI Monogr 1986;(1):135-7. Abstract

69. Henderson IC et al. Duration of therapy in adjuvant chemotherapy trials. NCI Monogr 1986;(1):95-8. Abstract

70. Bellon JR et al. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. Int J Radiat Oncol Biol Phys 2000;48:393-7. Abstract

71. Cardoso F et al. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node-positive breast cancer: Results of a feasibility study. Anticancer Res 2001;21:789-95. Abstract

72. Crown J. Docetaxel: Overview of an active drug for breast cancer. Oncologist 2001;6 Suppl 3:1-4. Abstract

73. Henderson IC. Adjuvant chemotherapy: Taxanes — the “pro:” position. NIH Consensus Conference on Early Breast Cancer, 2000. Abstract

74. Mamounas EP, Sledge GW Jr. Combined anthracycline-taxane regimens in the adjuvant setting. Semin Oncol 2001;28(4 Suppl 12):24-31. Abstract

75. Nabholtz JM et al. Chemotherapy of breast cancer: Are the taxanes going to change the natural history of breast cancer? Expert Opin Pharmacother 2000;1:187-206. Abstract

76. Nabholtz JM et al. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer. Semin Oncol 2000;27: 11-8. Abstract

77. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001;6 Suppl 3:30-5. Abstract

78. Piccart MJ. Taxanes in the adjuvant setting: Why not yet? NIH Consensus Conference on Early Breast Cancer, 2000. Abstract

79. Ravdin PM. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer. Semin Oncol 1999;26:20-3. Abstract

80. Baum M. Use of aromatase inhibitors in the adjuvant treatment of breast cancer. Endocr Relat Cancer 1999;6(2):231-4. Full-Text

81. Harper-Wynne C, Dowsett M. Recent advances in the clinical application of aromatase inhibitors. J Steroid Biochem Mol Biol 2001;76(1-5):179-86. Abstract

82. Ingle JN. Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention. Oncology (Huntingt) 2001;15(5 Suppl 7):28-34. Abstract

83. Kuerer HM et al. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. J Surg Oncol 2001;77(2):139-47. Abstract

84. Mannucci PM et al. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med 1996;156(16):1806-10. Abstract

85. McDonald CC et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ1995;311(7011):977-80. Full-Text

86. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998;45(6):608-12. Abstract

87. Muss HB. Role of adjuvant endocrine therapy in early-stage breast cancer. Semin Oncol 2001;28(4):313-21. Abstract

88. Pritchard KI et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996;14(10):2731-7. Abstract

89. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer and thromboembolic episodes. J Clin Oncol 1998;16(6):2018-24. Abstract

90. Antman KH. Randomized trials of high-dose chemotherapy for breast cancer. Biochem Biophys Acta 2001;1471(3):M89-98. Abstract

91. Armstrong DK, Davidson NE. Dose intensity for breast cancer. Oncology (Huntingt) 2001;15(6):701-8, 712. Abstract

92. Baynes RD et al. High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: Past or future? Semin Oncol 2001;28(4):377-88. Abstract

93. Mayer A, Earl H. Whither high-dose chemotherapy in breast cancer? Breast Cancer Res 2001;3(1):8-10. Abstract

94. Nieto Y et al. Status of high-dose chemotherapy for breast cancer: A review. Biol Blood Marrow Transplant 2000;6(5):476-95. Abstract

95. Peters WP et al. High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. Oncologist 2000;5(1):1-13. Abstract

96. Rodenhuis S. The status of high-dose chemotherapy in breast cancer. Oncologist 2000;5(5):369-75. Abstract

OTHER RESOURCES

ASCO Policy Statement: High-Dose Chemotherapy With Bone Marrow Transplant For Breast Cancer Patients. Web link

International Bone Marrow Transplant Registry/Autologous Blood & Marrow Transplant Registry. Web link

97. Bines J et al. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14(5):1718-29. Abstract

98. Blumenfeld Z. Ovarian rescue/protection from chemotherapeutic agents. J Soc Gynecol Investig. 2001;8(1 Suppl Proceedings):S60-4. Abstract

99. Del Mastro Let al. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: Prognostic role and clinical implications. Breast Cancer Res Treat 1997;43(2):183-90. Abstract

100. Goodwin PJ et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17(8):2365-2370. Abstract

101. Lower EE et al. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med 1999;8(7):949-54. Abstract

102. Moore HC. Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer. Curr Oncol Rep 2000;2(6):587-93. Abstract

103. Fox KR et al. Preventing chemotherapy-associated amenorrhea (CRA) with leuprolide in young women with early-stage breast cancer. Proc ASCO 2001; Abstract 98.

104. Laufer MR et al. Inducing amenorrhea during bone marrow transplantation. A pilot study of leuprolide acetate. J Reprod Med 1997;42(9):537-41. Abstract

SELECT, CURRENT PHASE III TRIALS OF ADJUVANT SYSTEMIC THERAPY

CLB-49907: Phase III Randomized Study of Adjuvant Chemotherapy Using Standard Cyclophosphamide/Methotrexate/Fluorouracil (CMF) or Doxorubicin/Cyclophosphamide (AC) Versus Oral Capecitabine in Elderly Women With Operable Adenocarcinoma of the Breast. Protocol

NSABP-B-30: Phase III Randomized Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Docetaxel Versus Doxorubicin and Docetaxel Versus Doxorubicin, Docetaxel, and Cyclophosphamide in Women With Breast Cancer and Positive Axillary Lymph Nodes. Protocol

NSABP-B-31: Phase III Randomized Study of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab (Herceptin) in Women With Node-Positive Breast Cancer That Overexpresses HER2. Protocol

NSABP-B-33: Phase III Randomized Study of Exemestane in Postmenopausal Women With Resected Stage I, II, or IIIA Breast Cancer Who Have Completed Five Years of Tamoxifen. Protocol

UCLA-010200601: Phase III Randomized Study of Adjuvant Doxorubicin, Cyclophosphamide, and Docetaxel With or Without Trastuzumab (Herceptin) Versus Trastuzumab, Docetaxel, and Either Carboplatin or Cisplatin in Women With HER2-neu-Expressing Node-Positive or High-Risk Node-Negative Operable Breast Cancer. Protocol

Home · Search